SMYRNA, Ga., Oct. 5, 2021 /PRNewswire/ — Ridgeview Institute is modernizing the standard of care for behavioral health treatment for Georgians in need of mental health and addiction services, thanks to a new partnership with GeneSight®.
The GeneSight® test, offered through Myriad Genetics, Inc. (NASDAQ: MYGN), helps clinicians understand how a particular individual may respond to certain medications by analyzing how a person’s genes impact how they may break down or respond to medications commonly prescribed to treat depression, anxiety and other psychiatric conditions.